Morphic — Technical Presentation (October 2023)
32 slides from Morphic's technical presentation, Oct 12, 2023
Slide 1: EMERALD-1 Full Data Presentation
EMERALD-1 Full Data Presentation October 12, 2023
Slide 2: Forward-Looking Statements
This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing clinical trials and related data, updates
Slide 3: Phase 2a Study Designed to Confirm Efficacy Signal: Results Exceeded Expectations
• Primary endpoint achieved, with consistent and expected clinical improvement seen across key measures • PK in patients consistent with healthy volunteers • RO and T-cell subsets consistent with healthy volunteers • Generally well tolerated with no safety signal observed • Further clinical improvem
Slide 4: Agenda
• Welcome and Introduction – Chris Erdman, SVP Investor & Corporate Communications • Trial Design, Patient Disposition, Safety, PK/PD – Dr. Brihad Abhyankar, SVP Clinical Development, Morphic Therapeutic • Detailed Clinical Efficacy Results – Dr. Bruce Rogers, President, Morphic Therapeutic • Conclu
Slide 5: EMERALD-1 Trial Design and Patient Disposition
EMERALD-1 Trial Design and Patient Disposition
Slide 6: MORF-057 Phase 2a EMERALD-1 Study Design
6 MORF-057 Phase 2a EMERALD-1 Induction Period (12 weeks) Maintenance Period (40 weeks) Primary Endpoint: Change in RHI measured at 12 weeks Secondary Endpoint: Change in the mMCS from baseline at w12 Open-label Extension Study (6 months) Safety Follow-Up Period Screening Period Target enrollment: 3
Slide 7: Baseline Patient Demographics: Moderately-to-Severely Active UC Population
Category Patients, N=35 Age, mean ± SD Years 39.2 ± 14.1 Sex, n (%) Female 16 (45.7) Geography, n (%) Poland United States 28 (80.0) 7 (20.0) Duration of disease, mean ± SD Years 7.5 ± 8.0 Extent of disease, n (%) Proctosigmoiditis L-sided colitis Pancolitis 12 (34.3) 10 (28.6) 10 (28.6) RHI Score,
Slide 8: Demographics and Baseline Characteristics by Prior Treatment Status & MES
8 Demographics and Baseline Characteristics by Prior Treatment Status & Mayo Endoscopic Score Baseline Characteristics Main Cohort (N=35) AT-N (N=21, 60%) AT-E (N=14, 40%) MES =2 (N=18, 51.4%) MES =3 (N= 17, 48.6%) Age, years, mean (SD) 39.2 (14.10) 39.9 (14.89) 38.3 (13.32) 40.1 (11.22) 38.4 (16.95
Slide 9: Safety and Tolerability
ZAMORPHIC Safety and Tolerability
Slide 10: MORF-057: Generally Well-Tolerated in EMERALD-1, No Safety Signal Observed
Endpoint Patients, N = 35 Patients with ≥1 TEAE, n (%) 12 (34.3) Serious TEAEs, n (%) 0 Patients with AE leading to death, n (%) 0 Patients with any grade 3 TEAEs, n (%) UC exacerbationa 2 (5.7) Common TEAEs (>5%), n (%) UC exacerbation Anemiab,c 4 (11.4) 3 (8.6) Treatment-related TEAE, n (%) 2 (5.7
Slide 11: PK/PD and Biomarker Data
PK/PD and Biomarker Data
Slide 12: Patient α4β7 Receptor Occupancy Consistent with Healthy Volunteer RO
• a4β7 RO achieved early and sustained saturating levels • a4β1 RO remained at low levels • No lymphocytosis or changes to circulating naïve T-cells were observed • a4β1 projected RO was below the limit of quantitation with mean trough value estimated to be <15% 12 Patient a4β7 Receptor Occupancy (R
Slide 13: Substantial Lymphocyte Subset Changes Consistent With Engagement Of α4β7
13 Substantial Lymphocyte Subset Changes Observed, Consistent With Engagement Of α4β7 0 25 50 75 100 125 150 Weeks N or m al iz ed % 0 2 6 12 0 25 50 75 100 125 150 200 300 400 Weeks N or m al iz ed % P = 0.0039 ** 0 2 6 12 P = 0.0298 * 0 25 50 75 100 125 150 200 300 400 Weeks N or m al iz ed % 0 2
Slide 14: Fecal Calprotectin Decreases Correlated with Disease Improvement
14 Fecal Calprotectin Decreases Correlated with Disease Improvement 19% 54% 75% Overall (n=29): 35% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Non- Responder (n=16) Clinical Response (n=13) Clinical Remission (n=8) -11% -86% -89% Overall (n=27): -56% -100% -90% -80% -70% -60% -50% -40% -30% -20% -1
Slide 15: Expected Changes in C-Reactive Protein Observed
15 Expected Changes in C-Reactive Protein Observed 18% 33% 33% Overall (n=17): 24% 0% 5% 10% 15% 20% 25% 30% 35% 40% Non-Responder (n=11) Clinical Response (n=6) Clinical Remission (n=3) No inclusion/exclusion criteria for CRP levels: n= 17 pts with baseline > 3 mg/L Patients experiencing clinical r
Slide 16: Clinical Efficacy Results
ZAMORPHIC Clinical Efficacy Results
Slide 17: Robarts Histopathology Index for UC
• RHI: a validated histology index derived from the Geboes Score and designed to be reproducible and responsive to clinically meaningful change in disease activity in UC over time • Calculated by evaluating 4 centrally read, individually weighted histologic items, each on a scale from 0 to 3 • RHI =
Slide 18: Modified Mayo Clinic Score for UC
18 Modified Mayo Clinic Score for UC • Modified Mayo Clinic Score (mMCS) – Three component score – 0 to 9 scale with moderate to severe UC 5 to 9 – Clinical Remission • SFS ≤ 1 • RBS = 0 • MES ≤ 1 without friability – Endoscopic Response / Improvement: MES ≤ 1 – Symptomatic Remission: SFS = 0 (or =
Slide 19: Primary Endpoint Met with High Statistical Significance
19 Endpoint @ Week 12 Overall (N=35) Change in RHI, Mean (SD) -6.4 (11.18) p=0.0019 RHI remission, n (%) 8 (22.9%) Clinical response (mMCS)1, n (%) 16 (45.7%) Clinical remission (mMCS)2, n (%) 9 (25.7%) Endoscopic Response/Improvement3, n (%) 9 (25.7%) Change from baseline to Week 12 in the Modified
Slide 20: EMERALD-1 Efficacy Results by AT Status and MES
20 EMERALD-1 Efficacy Results by AT Status and MES Endpoint @ Week 12 Overall N=35 AT-naïve n=21 AT- experienced n=14 MES =2 n=18 MES =3 n= 17 Change in RHI, mean ± SD -6.4 ± 11.2 -7.4 ± 11.9 -4.8 ± 10.3 -6.9 ± 12.1 -5.8 ± 10.4 RHI change ≥ 7 points, n (%) 17 (48.6) 12 (57.1) 5 (35.7) 10 (55.6) 7 (4
Slide 21: Consistent Across-the-Board Efficacy Signals Observed
21 Consistent “Across-the-Board” Efficacy Signals Observed Subgroup AT-Experienced Yes (n=14) No (n=21) Corticosteroid Use at Baseline Yes (n=9) No (n=26) Baseline MES 3 (n=17) 2 (n=18) Mean Change (95% CI) -4.8 (-10.7, 1.1) -7.4 (-12.8, -2.0) -5.2 (-11.1, 0.7) -6.8 (-11.7, -1.8) -5.8 (-11.1, -0.4)
Slide 22: Clinical Improvement in >75% of All Patients
22 Clinical Improvement in >75% of All Patients, Regardless of Prior Therapy and Baseline MES 77% 46% 26% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Improvement in mMCS Clinical Response Clinical Remission Overall Clinical Improvement AT-Naïve: n=21; AT-Experienced: n=14 76% 52% 43% 79% 36% 0% 0% 10% 20
Slide 23: Change in Central mMCS By Patient from Baseline
23 Change in Central mMCS By Patient from Baseline at Week 12 -7 -6 -5 -4 -3 -2 -1 0 1 2 Ch an ge in m M CS fr om B as el in e at W ee k 12
Slide 24: Change in Central mMCS from Baseline by Subgroup at Week 12
24 Change in Central mMCS from Baseline by Subgroup at Week 12 -7 -6 -5 -4 -3 -2 -1 0 1 2 Ch an ge in m M CS fr om B as el in e at W ee k 12 AT-Naïve Baseline MES = 3 AT-Naïve Baseline MES = 2 AT-Experienced Baseline MES = 3 AT-Experienced Baseline MES = 2 Response Remission
Slide 25: Data Beyond 12 Weeks
ZAMORPHIC Data Beyond 12 weeks
Slide 26: Symptomatic Remission By AT-Status
26 Symptomatic Remission By AT-Status: Week 44 Intent to Treat (ITT): Denominator includes all enrolled patients (N=35) As observed: Denominator includes only patients who completed the visit 14.3 7.1 11.4 42.9 7.1 28.6 47.6 7.1 31.4 42.9 21.4 34.3 47.6 28.6 40 42.9 28.6 37.1 42.9 21.4 34.3 3/21 9/2
Slide 27: Symptomatic Remission By Baseline MES
27 Symptomatic Remission By Baseline MES: Week 44 ITT: Denominator includes all enrolled patients (N=35) As observed: Denominator includes only patients who completed the visit 11.111.8 11.4 44.4 11.8 28.6 38.9 23.5 31.4 44.4 23.5 34.3 55.6 23.5 40 55.6 17.6 37.1 50 17.6 34.3 2/18 8/18 7/18 8/18 10/
Slide 28: PRO2 Scores by Subgroup
28 PRO2 (SFS+RBS) Scores by Subgroup: Week 44 PRO2 (Sum of Stool Frequency and Rectal Bleeding Scores) by AT-Status PRO2 (Sum of Stool Frequency and Rectal Bleeding Scores) by Baseline Endoscopy Score 4.2 3 1.8 1.8 1 0.9 1.1 0.9 4.2 4.2 3.3 3.1 3.1 2.4 2.6 2.2 2.1 1.5 2 1.3 2.3 1.5 2.3 1.4 18 18 18
Slide 29: Phase 2a Study Designed to Confirm Efficacy Signal: Results Exceeded Expectations
• Primary endpoint achieved, with consistent and expected clinical improvement seen across key measures • PK in patients consistent with healthy volunteers • RO and T-cell subsets consistent with healthy volunteers • Generally well tolerated with no safety signal observed • Further clinical improvem
Slide 30: Corporate Update
Corporate Update
Slide 31: MORF-057 and Corporate Guidance
31 MORF-057 and Corporate Guidance MORF-057 • EMERALD-1 maintenance phase continuing on track • EMERALD-2 enrolling on track • 1H25 primary endpoint data • Phase 2b in Crohn’s on track for ’24 initiation EMERALD-1 Phase 2a EMERALD-2 Phase 2b Crohn’s Phase 2b MORF-057 Phase 3 MORF-057 Phase 3 MORF-05
Slide 32: Q&A Participants
32 Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been
Morphic Holding — Technical Presentation (October 2023) on 6ix